Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00362
|
|||||
| Drug Name |
Ivosidenib
|
|||||
| Synonyms |
(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Ivosidenib; Ivosidenib (USAN/INN); Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Tibsovo
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute myeloid leukemia [ICD11: 2A60] | Approved | [1] | |||
| Cholangiocarcinoma [ICD11: 2C12.10] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C28H22ClF3N6O3
|
|||||
| Canonical SMILES |
C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
|
|||||
| InChI |
InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
|
|||||
| InChIKey |
WIJZXSAJMHAVGX-DHLKQENFSA-N
|
|||||
| CAS Number |
CAS 1448347-49-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 583 | Topological Polar Surface Area | 119 | ||
| Heavy Atom Count | 41 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
3.4
|
|||||
| PubChem CID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ivosidenib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB14568) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.